These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 8371585)
21. Interleukin-2 +/- lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Fefer A; Benyunes M; Higuchi C; York A; Massumoto C; Lindgren C; Buckner CD; Thompson JA Acta Haematol; 1993; 89 Suppl 1():2-7. PubMed ID: 8475668 [TBL] [Abstract][Full Text] [Related]
22. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
23. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Benyunes MC; Higuchi C; York A; Lindgren C; Thompson JA; Buckner CD; Fefer A Bone Marrow Transplant; 1995 Aug; 16(2):283-8. PubMed ID: 7581149 [TBL] [Abstract][Full Text] [Related]
24. Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease. Boughton BJ; Simpson AW Cytokines Cell Mol Ther; 1999 Mar; 5(1):1-6. PubMed ID: 10390074 [TBL] [Abstract][Full Text] [Related]
25. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity. Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327 [TBL] [Abstract][Full Text] [Related]
26. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia. Zhou MX; Findley HW; Davis R; Ragab AH Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987 [TBL] [Abstract][Full Text] [Related]
27. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4. Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200 [TBL] [Abstract][Full Text] [Related]
29. Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells. Archimbaud E; Thomas X; Campos L; Magaud JP; Fiere D; Doré JF Leukemia; 1991 Nov; 5(11):967-71. PubMed ID: 1961038 [TBL] [Abstract][Full Text] [Related]
30. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production. Klingemann HG; Neerunjun J; Schwulera U; Ziltener HJ Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589 [TBL] [Abstract][Full Text] [Related]
31. Induction of a syngeneic graft-versus-leukemia effect following bone marrow transplantation for chronic myeloid leukemia. Mackinnon S; Hows JM; Goldman JM Leukemia; 1990 Apr; 4(4):287-91. PubMed ID: 2366584 [TBL] [Abstract][Full Text] [Related]
32. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity. Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379 [TBL] [Abstract][Full Text] [Related]
33. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia. Parrado A; Casares S; Rodríguez-Fernández JM Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078 [TBL] [Abstract][Full Text] [Related]
34. High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2. Uharek L; Zeis M; Glass B; Steinmann J; Dreger P; Gassmann W; Schmitz N; Müller-Ruchholtz W Leukemia; 1996 Nov; 10(11):1758-64. PubMed ID: 8892679 [TBL] [Abstract][Full Text] [Related]
35. Proliferation and cytolytic function of anti-CD3 + interleukin-2 stimulated peripheral blood mononuclear cells following bone marrow transplantation. Katsanis E; Anderson PM; Filipovich AH; Hasz DE; Rich ML; Loeffler CM; Ochoa AC; Weisdorf DJ Blood; 1991 Sep; 78(5):1286-91. PubMed ID: 1831682 [TBL] [Abstract][Full Text] [Related]
36. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism. Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540 [TBL] [Abstract][Full Text] [Related]
37. Antileukemia activity of a natural killer cell line against human leukemias. Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753 [TBL] [Abstract][Full Text] [Related]
38. Adhesion molecules on MHC-nonrestricted lymphocytes: high density expression and role in oncolysis. Savary CA; Lotzová E Lymphokine Cytokine Res; 1992 Jun; 11(3):149-56. PubMed ID: 1391234 [TBL] [Abstract][Full Text] [Related]
39. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887 [TBL] [Abstract][Full Text] [Related]
40. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues. Colquhoun SD; Economou JS; Shau H; Golub SH J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]